Moleculin Biotech, Inc./$MBRX
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Moleculin Biotech, Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Ticker
$MBRX
Sector
Primary listing
Employees
17
Headquarters
Website
MBRX Metrics
BasicAdvanced
$13m
-
-$28.42
1.67
-
Price and volume
Market cap
$13m
Beta
1.67
52-week high
$7.98
52-week low
$1.79
Average daily volume
109k
Financial strength
Current ratio
1.413
Quick ratio
1.296
Long term debt to equity
1.479
Total debt to equity
2.392
Profitability
EBITDA (TTM)
-25.013
Management effectiveness
Return on assets (TTM)
-80.35%
Return on equity (TTM)
-256.05%
Valuation
Price to book
0.54
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
-0.131
Free cash flow yield (TTM)
-764.70%
Free cash flow per share (TTM)
-19.193
Growth
Earnings per share change (TTM)
-84.97%
3-year earnings per share growth (CAGR)
-57.89%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moleculin Biotech, Inc. stock?
Moleculin Biotech, Inc. (MBRX) has a market cap of $13M as of April 30, 2026.
What is the P/E ratio for Moleculin Biotech, Inc. stock?
The price to earnings (P/E) ratio for Moleculin Biotech, Inc. (MBRX) stock is 0 as of April 30, 2026.
Does Moleculin Biotech, Inc. stock pay dividends?
No, Moleculin Biotech, Inc. (MBRX) stock does not pay dividends to its shareholders as of April 30, 2026.
When is the next Moleculin Biotech, Inc. dividend payment date?
Moleculin Biotech, Inc. (MBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Moleculin Biotech, Inc.?
Moleculin Biotech, Inc. (MBRX) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.